A Quality-Adjusted Survival (Q-TWiST) Analysis to Assess Benefit-Risk of Acalabrutinib Versus Idelalisib/Bendamustine Plus Rituximab or Ibrutinib Among Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Patients

MLA

Ling Cai, et al. “A Quality-Adjusted Survival (Q-TWiST) Analysis to Assess Benefit-Risk of Acalabrutinib Versus Idelalisib/Bendamustine Plus Rituximab or Ibrutinib Among Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Patients.” Blood, vol. 138, Nov. 2021, p. 3722. EBSCOhost, https://doi.org/10.1182/blood-2021-147112.

APA

Ling Cai, John F. Seymour, Anthony R. Mato, Priyanka Gaitonde, & Ugochinyere Emeribe. (2021). A Quality-Adjusted Survival (Q-TWiST) Analysis to Assess Benefit-Risk of Acalabrutinib Versus Idelalisib/Bendamustine Plus Rituximab or Ibrutinib Among Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Patients. Blood, 138, 3722. https://doi.org/10.1182/blood-2021-147112

Chicago

Ling Cai, John F. Seymour, Anthony R. Mato, Priyanka Gaitonde, and Ugochinyere Emeribe. 2021. “A Quality-Adjusted Survival (Q-TWiST) Analysis to Assess Benefit-Risk of Acalabrutinib Versus Idelalisib/Bendamustine Plus Rituximab or Ibrutinib Among Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Patients.” Blood 138 (November): 3722. doi:10.1182/blood-2021-147112.